An interventional study of Pomegranate Seed Oil Supplementation in Palliative Care Patients with Advanced Dementia and Care-as-usual in Urinary Tract Infections (UTIs), Urinary Tract Infection, Recurrent and Antipsychotics Discontinuation, sponsored by Panhellenic Federation of Alzheimer's Disease and Related Disorders. Completed at 1 site in Greece. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-02-25.
Sponsored by Panhellenic Federation of Alzheimer's Disease and Related Disorders · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Urinary Tract Infections with a site in Greece — 1 open to participants now, 2 under way, none of them phase 3. Urinary Tract Infections · Greece.
Among the 20 studies in Urinary Tract Infections with a site in Greece, this one is the 11th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2024, is the only one with no phase, and was the 20th registered.
808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.
Browse Urinary Tract Infections studies →1 of the 20 studies in Urinary Tract Infections with a site in Greece is open now. Recruiting first, the newest first:
Infectopharm Arzneimittel GmbH · Sites in Greece, Austria, Germany and 2 more countries
Ages 18+
A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →
Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 7
First in 2007; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 131 across 564 interventional studies indexed under Urinary Tract Infections.
Median enrollment 296 across the 12 interventional studies, 1,014 across the 8 observational. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 20 have an industry lead sponsor. The 10 most frequent:
Panhellenic Federation of Alzheimer's Disease and Related Disorders is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Panhellenic Federation of Alzheimer's Disease and Related Disorders has 1 study filed under Urinary Tract Infections — fewer than ten, so there is no comparison to draw.
1 of the studies in Urinary Tract Infections with a site in Greece that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06672978Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies in Urinary Tract Infections with a site in Greece, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical study is to learn if Pomegranate Seed Oil supplementation works to combat urinary tract infections, recurrenturinary tract infections, or pneumonia and contributes to the tapering or discontinuation of antipsychotics in palliative care patients withadvanced dementia.
The main questions it aims to answer are:
Researchers will compare Pomegranate Seed Oil to care-as-usual to see if Pomegranate Seed Oil supplementation can increase quality of care in palliative care patients with advanced dementia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Pomegranate Seed Oil Supplementation in Palliative Care Patients with Advanced Dementia
Other: Care-as-usual
Besides Pomegranate Seed Oil Supplementation, all participants will continue to receive all ongoing care and treatments, including following the Mediterranean diet, monthly neuropsychological and behavioural assessments, physiotherapy, cognitive stimulation, occupational therapy and music therapy, without any modification
All participants will continue to receive all ongoing care and treatments, including a Mediterranean diet,monthly neuropsychological and behavioural assessments, physiotherapy, cognitive stimulation,occupational therapy and music therapy, without any modification
Number of Palliative Care Patients with Advanced Dementia with Urinary Tract Infections (UTIs)
Urinary Tract Infections were diagnosed using the revised McGeer criteria for the diagnosis of UTIs in Stone et al. (2012): Criteria from both 1 and 2 1. At least 1 of the following: Acute dysuria or acute pain, swelling, or tenderness of the testes, epididymis, or prostate OR Fever or leukocytosis and at least 1 of the following localizing urinary tract sub-criteria: Acute costovertebral angle pain or tenderness Suprapubic pain Gross hematuria New or marked increase in incontinence New or marked increase in urgency New or marked increase in frequency In the absence of fever or leukocytosis, then 2 or more of the following: Suprapubic pain Gross hematuria New or marked increase in incontinence New or marked increase in urgency New or marked increase in frequency 2. One of the following: At least 10\^5 cfu/mL of no more than 2 species of microorganisms in a voided urine sample At least 10\^2 of any number of organisms in a specimen collected by in-and-out catheter
Time frame: From enrollment to the end of treatment at 24 weeks
Number of Palliative Care Patients with Advanced Dementia with Reccurent Urinary Tract Infections (rUTIs)
Recurrent UTIs were classified as more than one UTI diagnosed in a single patient based on the criteria proposed in Stone et al. (2012) as described previously.
Time frame: From enrollment to the end of treatment at 24 weeks
Number of Palliative Care Patients with Advanced Dementia with Antipsychotic Deprescribing (Dose Reduction or Discontinuation)
Time frame: From enrollment to the end of treatment at 24 weeks
Number of Palliative Care Patients with Advanced Dementia Diagnosed with Pneumonia
As in Stone et al. (2012): All 3 criteria must be present: 1. Interpretation of a chest radiograph as demonstrating pneumonia or the presence of a new infiltrate 2. At least 1 of the following respiratory subcriteria 1. New or increased cough 2. New or increased sputum production 3. O2 saturation \<94% on room air or a reduction in O2 saturation of \>3% from baseline 4. New or changed lung examination abnormalities 5. Pleuritic chest pain 6. Respiratory rate of ≥25 breaths/min 3. At least 1 of the following criteria 1. Fever 2. Leukocytosis 3. Acute change in mental status from baseline and either disorganized thinking or altered level of consciousness 4. Acute functional decline
Time frame: From enrollment to the end of treatment at 24 weeks
Plan to share: No — Data Availability Statement The data supporting the findings of this study will not be publicly available due to GAADRD's internal policy to maintain the privacy of research participants and patients. However, the data will be available on reasonable request from the corresponding author.
Ran from May 2024 to primary completion in Oct 2024, 5 months.
Of 136 non-industry interventional studies with no phase under Urinary Tract Infections, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 39. This study's 5 months is below that.
Counting every sponsor, half of 154 studies reached it within 22 months; a quarter within 8 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Panhellenic Federation of Alzheimer's Disease and Related Disorders